Biocon’s drug Itolizumab gets DCGI Nod for treatment of moderate to severe COVID patients – Republic World – Republic World
In a major breakthrough in the treatment of Coronavirus in India, Biocon’s drug Itolizumab received a nod by the Drugs Controller General of India (DCGI) for its use on moderat…
